Bicycle Therapeutics plc (FRA:50BA)

Market Cap	261.63M -37.6%
Revenue (ttm)	53.57M +217.4%
Net Income	-166.67M
EPS	-2.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.600
Previous Close	3.600
Day's Range	3.580 - 3.680
52-Week Range	3.180 - 7.550
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted imm...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 288
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 50BA

Financial Performance

In 2025, Bicycle Therapeutics's revenue was $72.59 million, an increase of 105.77% compared to the previous year's $35.28 million. Losses were -$218.96 million, 29.5% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error